- €797.12m
- €743.62m
- €19.52m
French and Benelux stocks-Factors to watch
Brief: Medincell FY Net Loss Widens To EUR 24.8 Mln
Brief: Medincell Pharma Names Richard Malamut As Chief Medical Officer
Brief: Mithra CDMO Announces Collaboration With MedinCell For Development Of Injectable Products For Malaria And Transplant Rejection
Teva Pharmaceuticals slide after FDA rejects schizophrenia treatment
Brief: MedinCell Announces Inclusion Of First Participants In New Covid-19 Prophylaxis Clinical Trial SAIVE
Brief: Medincell H1 Operating Loss Widens To EUR 11.2 Mln
Brief: Medincell Receives EUR 4 Mln In Funding From Bpifrance
Brief: Medincell: Phase 3 Data Of mdc-IRM Shows Significant Improvements In Patients With Schizophrenia
Brief: Teva And MedinCell Announce FDA Acceptance Of New Drug Application For TV-46000/mdc-IRM As A Treatment For Patients With Schizophrenia
Brief: Medincell FY Net Loss Narrows To EUR 19 Mln
Brief: MedinCell Targets Anti-Malaria Injectable First Clinical Trial In 2023
Brief: MedinCell Confirms Safety Of Continuous Administration of Ivermectin
Brief: MedinCell: Mdc-CWM Clinical Phase 3 Will Start In 2021
Brief: Medincell Publishes Ivermectin Safety Expert Analysis
Brief: Medincell Announces Capital Increase Of Ac. 30 Million Euros
Brief: Medincell Announces Three New Products Entering Regulatory Development
Brief: Medincell Announces Transfer Of Euronext Paris Shares From Compartment C To B On Jan 29, 2021
Brief: MedinCell To Resume Trading On Euronext Paris